Literature DB >> 20471822

A nomogram based on the expression of Ki-67, steroid hormone receptors status and number of chemotherapy courses to predict pathological complete remission after preoperative chemotherapy for breast cancer.

Marco Colleoni1, Vincenzo Bagnardi, Nicole Rotmensz, Giuseppe Viale, Mauro Mastropasqua, Paolo Veronesi, Anna Cardillo, Rosalba Torrisi, Alberto Luini, Aron Goldhirsch.   

Abstract

BACKGROUND: Tools able to predict pathological complete response (pCR) to preoperative chemotherapy might improve treatment outcome. PATIENTS AND METHODS: Data from 783 patients with invasive ductal carcinoma treated with preoperative chemotherapy and operated at the European Institute of Oncology were used to develop a nomogram using logistic regression model based on both categorical (clinical T and N, HER2/neu, grade and primary therapy) and continuous variables (age, oestrogen receptor (ER), progesterone receptor (PgR), Ki-67 expression and number of chemotherapy courses). The performance of the resulting nomogram was internally evaluated through bootstrapping methods. Finally the model was externally validated on a patient set treated in other institutions and subsequently operated at the EIO.
RESULTS: At multivariable analysis the probability of pCR was directly associated with Ki-67 expression (OR for 10% increase in the percentage of positive cells, 1.15, 95% confidence interval (CI), 1.03, 1.29) and number of chemotherapy courses (OR for one cycle increase, 1.31, 95% CI, 1.12, 1.53) and inversely associated with ER and PgR expression (ORs for 10% increase in the percentage of positive cells, 0.86, 95% CI 0.79, 0.93 and 0.82, 95% CI 0.69, 0.99, respectively). The nomogram for pCR based on these variables had good discrimination in training as well in validation set (AUC, 0.78 and 0.77).
CONCLUSION: The use of a nomogram based on the number of preoperative courses, degree of Ki-67 and steroid hormone receptors expression may be useful for predicting the probability of pCR and for the design of the proper therapeutic algorithm in locally advanced breast cancer. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471822     DOI: 10.1016/j.ejca.2010.04.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

1.  Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.

Authors:  Paula Cabrera-Galeana; Wendy Muñoz-Montaño; Fernando Lara-Medina; Alberto Alvarado-Miranda; Victor Pérez-Sánchez; Cynthia Villarreal-Garza; R Marisol Quintero; Fany Porras-Reyes; Enrique Bargallo-Rocha; Ignacio Del Carmen; Alejandro Mohar; Oscar Arrieta
Journal:  Oncologist       Date:  2018-02-28

2.  A clinical prediction model to stratify retinopathy of prematurity risk using postnatal weight gain.

Authors:  Gil Binenbaum; Gui-shuang Ying; Graham E Quinn; Stephan Dreiseitl; Karen Karp; Robin S Roberts; Haresh Kirpalani
Journal:  Pediatrics       Date:  2011-02-14       Impact factor: 7.124

3.  Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR.

Authors:  Ramesh Omranipour; Roghiyeh Jalili; Adel Yazdankhahkenary; Abdolali Assarian; Mehrzad Mirzania; Bita Eslami
Journal:  Eur J Breast Health       Date:  2020-07-01

4.  Pathological complete response in younger and older breast cancer patients.

Authors:  Agnieszka Kołacińska; Justyna Chałubińska; Maria Błasińska-Morawiec; Izabela Dowgier-Witczak; Wojciech Fendler; Radzisław Kordek; Zbigniew Morawiec
Journal:  Arch Med Sci       Date:  2012-05-09       Impact factor: 3.318

5.  Nomogram for predicting breast conservation after neoadjuvant chemotherapy.

Authors:  Min Kyoon Kim; Wonshik Han; Hyeong-Gon Moon; Soo Kyung Ahn; Jisun Kim; Jun Woo Lee; Ju-Yeon Kim; Taeryung Kim; Kyung-Hun Lee; Tae-Yong Kim; Sae-Won Han; Seock-Ah Im; Tae-You Kim; In Ae Park; Dong-Young Noh
Journal:  Cancer Res Treat       Date:  2014-09-04       Impact factor: 4.679

6.  Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer.

Authors:  T Fujii; T Kogawa; W Dong; A A Sahin; S Moulder; J K Litton; D Tripathy; T Iwamoto; K K Hunt; L Pusztai; B Lim; Y Shen; N T Ueno
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

7.  Nomogram for prediction of pathologic complete remission using biomarker expression and endoscopic finding after preoperative chemoradiotherapy in rectal cancer.

Authors:  Hyuk Hur; Min Soo Cho; Woong Sub Koom; Joon Seok Lim; Tae Il Kim; Joong Bae Ahn; Hoguen Kim; Nam Kyu Kim
Journal:  Chin J Cancer Res       Date:  2020-04       Impact factor: 5.087

8.  Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype.

Authors:  Masumi Yanagawa; Kenzo Ikemot; Shigeto Kawauchi; Tomoko Furuya; Shigeru Yamamoto; Masaaki Oka; Atunori Oga; Yukiko Nagashima; Kohsuke Sasaki
Journal:  BMC Res Notes       Date:  2012-07-25

9.  Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.

Authors:  G Allevi; C Strina; D Andreis; V Zanoni; L Bazzola; S Bonardi; C Foroni; M Milani; M R Cappelletti; F Gussago; S Aguggini; R Giardini; M Martinotti; S B Fox; A L Harris; A Bottini; A Berruti; D Generali
Journal:  Br J Cancer       Date:  2013-04-11       Impact factor: 7.640

10.  Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer.

Authors:  V Petry; D M Gagliato; A I C Leal; R J Arai; E Longo; F Andrade; M D Ricci; J R Piato; R Barroso-Sousa; P M Hoff; M S Mano
Journal:  Braz J Med Biol Res       Date:  2015-03-06       Impact factor: 2.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.